Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In fibrotic NASH, treatment with miR-223 3p led to a remarkable mitigation of fibrosis development and activation of hepatic stellate cells (HSCs). miR-223 3p disrupted the activation of the NLRP3 inflammasome by impairing the synthesis of cleaved interleukin-1β (IL-1β), mature IL-1β, and NLRP3, and the activation of caspase-1 p10 in both EAH and fibrotic NASH.
|
31585800 |
2020 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Secondly, the results of IHC staining indicated that the expressions of CLS1 and NLRP3 in liver tissues were significantly upregulated in the NASH group compared to the ND group.
|
31599445 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings suggest that impaired mitophagy triggers hepatic NLRP3 inflammasome activation in a murine NASH model and primary hepatocytes.
|
30700851 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that liraglutide suppresses NLRP3 inflammasome-induced hepatocyte pyroptosis via mitophagy to slow the progression of NASH.
|
31593687 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings demonstrated that inhibited the activation of the TXNIP-NLRP3 axis reduced MPO activity and oxidative stress and thus restoring the intestinal barrier function in NASH.
|
30387131 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
NLRP3, ASC and Caspase-1 protein expression levels in KCs from NASH mouse livers were significantly higher than those in KCs from NLRP3<sup>-/-</sup> mice, and the number of NLRP3 inflammasome protein complexes was significantly higher in KCs from NASH mouse livers, whereas these protein complexes could not be formed in NLRP3<sup>-/-</sup> mice.
|
30103942 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the suppression of the NLRP3/6 inflammasome pathway and NF-κB activation may partly contribute to the reduction of the hepatic injury during the progression of NASH by therapeutic LBP treatment.
|
30266645 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
NLRP3-/- mice exhibited less severe NASH than WT mice in MCD diet model, whereas TXNIP deficiency enhanced NLRP3 inflammasome activation and exacerbated liver injury.
|
28499273 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed at investigating the role of the purinergic receptor 2X<sub>7</sub> (PR2X<sub>7</sub>), through the NLRP3 inflammasome, in the development of NASH.
|
29270247 |
2017 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we hypothesize an amplifying loop among lipogenesis, palmitate, Nrf2 and Nlrp3 that leads to a higher risk of NAFLD progression to NASH in a high-fructose diet compared to a high-saturated fat intake.
|
28189916 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
ANDRO has been also shown to inhibit the NLRP3 inflammasome, a relevant pathway in NASH.
|
28615649 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that KCs and NLRP3 play pro-inflammatory roles in the progression of NASH, probably through secretions of IL-1β and IL-18 by KCs induced by PA. PA could act as a kind of damage-associated molecular patterns to elevate the messenger RNA and protein expression levels of NLRP3, ASC, and caspase-1 in KCs from WT mice.
|
28730512 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that (1) Elovl6 is a critical modulator for atherogenic high-fat diet-induced inflammation, oxidative stress, and fibrosis in the liver; (2) Elovl6 expression is positively correlated with severity of hepatosteatosis and liver injury in NASH patients; and (3) deletion of Elovl6 reduces palmitate-induced activation of the NLR family pyrin domain-containing 3 inflammasome; this could be at least one of the underlying mechanisms by which Elovl6 modulates the progress of NASH.
|
22753171 |
2012 |